I dag er der et interview med Jan Van der Vinkel i Wall Street Journal, som måske kan forklare lidt af den opgang i kursen vi ser idag.
I interviewet forklarer han beslutningen med Zalutumumab, som han overraskende kalder third-in-class drug, samtidigt med at han understreger at Big Pharma nu er villige til at betale for differentierede first-in-class drugs som Daratumumab.
Derudover gentager han målsætningen med at bringe et nyt stof ind om året i klinikken og blive ved med at udlicensiere stofferne for at supplere pengebjerget i Genmab.
I interviewet forklarer han beslutningen med Zalutumumab, som han overraskende kalder third-in-class drug, samtidigt med at han understreger at Big Pharma nu er villige til at betale for differentierede first-in-class drugs som Daratumumab.
Derudover gentager han målsætningen med at bringe et nyt stof ind om året i klinikken og blive ved med at udlicensiere stofferne for at supplere pengebjerget i Genmab.
28/6 2011 17:23 vouskootia 1
43509 http://www.genmab.com/Science%20And%20Research/LicensingOpportunities/Zalutumumab/ProvenTarget.aspx
Teknisk vel 4th in class? (potentielt nummer 4 til at enter market?)
http://www.genmab.com/Science%20And%20Research/LicensingOpportunities/Zalutumumab.aspx
"has the most promising overall mechanisms of action in its class" (best-in-class potentielt?)
Ps. et tip til WSJ - soeg paa google efter title og laes den fulde artikel gratis ved at klikke ind via google (ellers kraeves login)
dvs. soeg paa google efter "wsj genmab aims to milk pipeline".
Om Z-mab:
"We will definitely partner it at some point but it will take money to develop this product, and Genmab is not going to do that part," van de Winkel said.
Om daratumumab:
"We have had very extensive discussions already with Big Pharma and biotech companies with a view to eventually partnering that molecule, and right now the feedback has been hugely positive, so I don't think we'll have much trouble partnering in this new innovation ecosystem provided it's a first-in-class candidate."
Teknisk vel 4th in class? (potentielt nummer 4 til at enter market?)
http://www.genmab.com/Science%20And%20Research/LicensingOpportunities/Zalutumumab.aspx
"has the most promising overall mechanisms of action in its class" (best-in-class potentielt?)
Ps. et tip til WSJ - soeg paa google efter title og laes den fulde artikel gratis ved at klikke ind via google (ellers kraeves login)
dvs. soeg paa google efter "wsj genmab aims to milk pipeline".
Om Z-mab:
"We will definitely partner it at some point but it will take money to develop this product, and Genmab is not going to do that part," van de Winkel said.
Om daratumumab:
"We have had very extensive discussions already with Big Pharma and biotech companies with a view to eventually partnering that molecule, and right now the feedback has been hugely positive, so I don't think we'll have much trouble partnering in this new innovation ecosystem provided it's a first-in-class candidate."
29/6 2011 11:08 vouskootia 043545 Genmab snakkede jo forresten tidligere om at lave en pakke-deal med fabrik+zmab....
Hvis der er mere rift om Dmab - hvad med at lave en 3-in-one offer?
(hvis det giver nogen som helst mening?)
Hvis der er mere rift om Dmab - hvad med at lave en 3-in-one offer?
(hvis det giver nogen som helst mening?)6/7 2011 00:51 gentogen 043723 This abstract will not be presented at the 2011 ASCO Annual Meeting but has been published in conjunction with the meeting.
Abstract No:
e18571
Citation:
J Clin Oncol 29: 2011 (suppl; abstr e18571)
Author(s):
T. Mutis, M. de Weers, M. S. van der Veer, B. v. Kessel, J. M. Bakker, S. Wittebol, P. Parren, H. M. Lokhorst; UMC Utrecht, Utrecht, Netherlands; Genmab Utrecht, Utrecht, Netherlands; Meander Medisch Centrum, Amersfoort, Netherlands
Abstract:
Background: Multiple myeloma (MM) represents an incurable malignancy of antibody-producing clonal plasma cells. Over the past decade significant progress has been made in MM treatment using novel immunomodulating agents such as lenalidomide (LEN) and bortezomib (BORT). Daratumumab (DARA) is a first-in-class human therapeutic CD38-specific antibody with a broad mechanism of action. DARA mediates MM cell death primarily via ADCC (antibody dependent cellular cytotoxicity), CDC (complement dependent cytotoxicity) and apoptosis. We are currently exploring the possibility to further improve MM therapy by combining novel MM therapeutics with DARA. Our initial in vitro work already showed significantly improved MM cell killing by combining DARA with LEN treatment. Methods: In ex vivo assays, which allow us to address killing of MM cells in bone marrow aspirates isolated from MM patients, we now investigated whether the addition of DARA to the LEN+BORT combination significantly exceeds the effectiveness of LEN+BORT treatment alone. DARA was also combined with two recently introduced triple combination therapies: LEN, BORT, dexamethasone (RVD) and melphalan, prednisone, BORT (MPV). Results: we demonstrate that the addition of DARA to the LEN+BORT combination significantly exceeds the effectiveness of LEN+BORT treatment alone (P
Abstract No:
e18571
Citation:
J Clin Oncol 29: 2011 (suppl; abstr e18571)
Author(s):
T. Mutis, M. de Weers, M. S. van der Veer, B. v. Kessel, J. M. Bakker, S. Wittebol, P. Parren, H. M. Lokhorst; UMC Utrecht, Utrecht, Netherlands; Genmab Utrecht, Utrecht, Netherlands; Meander Medisch Centrum, Amersfoort, Netherlands
Abstract:
Background: Multiple myeloma (MM) represents an incurable malignancy of antibody-producing clonal plasma cells. Over the past decade significant progress has been made in MM treatment using novel immunomodulating agents such as lenalidomide (LEN) and bortezomib (BORT). Daratumumab (DARA) is a first-in-class human therapeutic CD38-specific antibody with a broad mechanism of action. DARA mediates MM cell death primarily via ADCC (antibody dependent cellular cytotoxicity), CDC (complement dependent cytotoxicity) and apoptosis. We are currently exploring the possibility to further improve MM therapy by combining novel MM therapeutics with DARA. Our initial in vitro work already showed significantly improved MM cell killing by combining DARA with LEN treatment. Methods: In ex vivo assays, which allow us to address killing of MM cells in bone marrow aspirates isolated from MM patients, we now investigated whether the addition of DARA to the LEN+BORT combination significantly exceeds the effectiveness of LEN+BORT treatment alone. DARA was also combined with two recently introduced triple combination therapies: LEN, BORT, dexamethasone (RVD) and melphalan, prednisone, BORT (MPV). Results: we demonstrate that the addition of DARA to the LEN+BORT combination significantly exceeds the effectiveness of LEN+BORT treatment alone (P
